{
    "url_original": "https://www.wsj.com/articles/fda-rejects-eli-lillys-china-developed-cancer-drug-11648131761?mod=business_lead_pos6",
    "url": "fda-rejects-eli-lillys-china-developed-cancer-drug-11648131761",
    "title": "FDA Rejects Eli Lilly’s China-Developed Cancer Drug",
    "sub_head": "Agency asked Lilly and its China-based partner to conduct another trial of the immunotherapy in multiple regions",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-511211?width=860&height=573",
    "image_1": "im-511211.jpg",
    "time": "2022-03-24 10:22:00",
    "body": "The U.S. Food and Drug Administration rejected an application by  Eli Lilly  & Co. and a China-based partner to sell a new lung-cancer drug in the U.S., after agency officials raised concerns about the medicine’s testing in China.<br />The FDA was unable to approve the application, and recommended that an additional clinical trial of the drug be conducted in multiple regions, Lilly said Thursday."
}